Document:

Exhibit
10.1

 

SECONDARY
STOCK PURCHASE AGREEMENT AND RELEASE

 

This
Secondary Stock Purchase Agreement and Release (this “Agreement”) is made and entered into as of October 03, 2022
(the “Effective Date”) among Phytotherapeutix Holdings Ltd., a United Kingdom entity
(“Phyto”), Equipped4 Holdings Limited, a United Kingdom entity (“Equipped”), TPR Global
Limited, a United Kingdom entity (“TPR”) (Phyto, Equipped and TPR, each, a “Seller” and
collectively, the “Sellers”), Bright Green Corporation, a Delaware corporation (the “Buyer”)
and Alterola Biotech Inc., a Nevada corporation (the “Company”).

 

RECITALS

 

WHEREAS,
each Seller is the holder of shares of Common Stock (the “Subject Stock”) of the Company; and

 

WHEREAS,
each Seller desires to sell and the Buyer desires to purchase the applicable Transferred Shares (as defined below) from each Seller upon
the terms and conditions set forth herein.

 

NOW
THEREFORE, in consideration of the mutual agreements contained in this Agreement, and intending to be legally bound by the terms
and conditions of this Agreement, the parties agree as follows:

 

1.
Sale and Purchase of Shares.

 

1.1
At the Closing (as defined below) and subject to the terms and conditions of this Agreement, the Buyer hereby agrees to purchase
from each Seller, and each Seller agrees to transfer, sell and deliver to the Buyer, all of the Seller’s right, title and interest
in and to the number, class and series of issued and outstanding shares of Subject Stock set forth as such Seller’s “Transferred
Shares” on Schedule 1 to this Agreement for the applicable purchase price set forth for such Seller’s shares on Schedule
1 to this Agreement (the “Purchase Price”) pursuant to the payment schedule set forth on Schedule 1 (the
“Payment Schedule”), provided that delivery of all of the Transferred Shares to the Buyer shall occur on the Closing.
“Transferred Shares” means all shares of Subject Stock of the Company sold to Buyer at the Closing pursuant to this
Section 1.1.

 

1.2
Each Seller agrees to, immediately following receipt of each installment payment of the Purchase Price pursuant to the Payment Schedule,
loan to the Company the proceeds such Seller received from the foregoing sale of its Transferred Shares pursuant to the Form of Loan
Agreement attached hereto as Exhibit A. The Company agrees that it shall use such loan proceeds for the purposes of developing
and perfecting its rights to its intellectual property, including paying staff and related operational requirements, and agrees that
time is of the essence for such development and perfection.

 

2.
The Closing.

 

2.1
The sale and purchase of the Transferred Shares shall take place on the Effective Date remotely via the exchange of documents, electronically
or otherwise (the “Closing”).

 

2.2
Deliveries and Conditions. Upon the Closing,

 

(a)
Each Seller shall deliver to the Company an Assignment Separate from Certificate in substantially the form attached hereto as Exhibit
B, executed by such Seller in favor of the Buyer for the applicable Transferred Shares;

 

    	 

     

    

 

(b)
Each Seller shall (A) instruct the Company to cancel the Original Stock Certificate(s) (if any) representing the applicable Transferred
Shares and to issue a notice of stock account evidencing the applicable Transferred Shares being purchased by the Buyer (the “Buyer
Stock Account Notice”), and (B) deliver to the Buyer a counterpart signature page to this Agreement executed by such Seller;

 

(c)
Each Seller shall instruct the Company to (A) deliver to the Buyer the Buyer Stock Account Notice representing the number of Transferred
Shares purchased by the Buyer, (B) if applicable, deliver to such Seller an updated notice of stock account for the balance of shares
of Subject Stock remaining after the transfer of the applicable Transferred Shares, and (C) register in its books and records the number
of the Transferred Shares sold and transferred by such Seller hereunder and the number of Transferred Shares acquired by the Buyer hereunder;

 

(d)
the Buyer shall deliver to each Seller a counterpart signature page to this Agreement executed by the Buyer;

 

(e)
the Sellers and the Buyer shall deliver to the Company their executed copy of this Agreement, which delivery shall be deemed instructions
to act as provided herein;

 

(f)
the Buyer shall pay the applicable portion of the Purchase Price pursuant to the Payment Schedule for each Seller’s Transferred
Shares to such Seller by wire transfer of

immediately
available funds to such Seller’s designated account upon the Buyer’s confirmation of receipt of the Buyer Stock Account Notice;

 

(g)
the Buyer shall have received a properly executed statement, issued by the Company pursuant to Treasury Regulations Sections 1.897-2(h)
and 1.1445-2(c)(3) dated no more than thirty (30) days prior to the Closing and signed by an officer of the Company, and in form and
substance reasonably satisfactory to the Buyer, certifying that interests in the Company do not constitute “United States real
property interests” under Section 897(c) of the Internal Revenue Code of 1986, as amended, and the Company shall have provided
notice to the IRS in accordance with the provisions of Treasury Regulations Section 1.897-2(h)(2);

 

(h)
the Sellers and the Buyer shall each execute the Voting Agreement in the form of Exhibit C hereto.

 

3.
Representations and Warranties of the Buyer. The Buyer represents and warrants to the Sellers and the Company as of the Effective
Date that:

 

3.1
Authorization. The Buyer has full power and authority to enter into and perform its obligations under this Agreement, and
this Agreement, when executed and delivered by the Buyer, shall constitute valid and legally binding obligations of the Buyer, enforceable
against the Buyer in accordance with its terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies. The execution, delivery and performance of
this Agreement, and the consummation of the transactions contemplated hereby, will not result in a violation of, or default under, any
instrument, judgment, order, writ, decree or contract applicable to the Buyer.

 

    	2

     

    

 

3.2
Purchase for Own Account for Investment. The Buyer is purchasing the Transferred Shares for investment purposes only and not
with a view to, or for sale in connection with, a distribution of the Transferred Shares within the meaning of the Securities Act of
1933, as amended (the “1933 Act”).

 

3.3
Understanding of Risks. The Buyer or its registered investment advisor is fully aware of: (a) the speculative nature of the
Transferred Shares, (b) the lack of liquidity of the Transferred Shares and the restrictions on transferability of the Transferred Shares,
and (c) the tax consequences of acquiring the Transferred Shares. The Buyer acknowledges that the Purchase Price represents a negotiated
price and may not reflect the fair market value of the Transferred Shares.

 

3.4
Accredited Investor. The Buyer is an “accredited investor” within the meaning of Rule 501(a) under the Securities
Act of 1933 (the “1933 Act”).

 

3.5
No General Solicitation or General Advertising. At no time was the Buyer presented with or solicited by any publicly issued
or circulated newspaper, mail, radio, television, internet or other form of “general advertising” or “general solicitation”
within the meaning of Rule 502(c) under the 1933 Act in connection with the Transferred Shares.

 

3.6
Compliance with Securities Laws. The Buyer understands and acknowledges that, in reliance upon the representations and warranties
made by the Seller and the Buyer herein and the bona fide nature of the Buyer’s investment intent, the offer and sale of the Transferred
Shares are not being registered with the Securities and Exchange Commission (“SEC”) under the 1933 Act, but instead
are being transferred under an exemption from the registration requirements of the 1933 Act.

 

3.7
Restricted Securities. The Buyer understands that the Transferred Shares are “restricted securities” under applicable
U.S. federal and state laws and that, pursuant to these laws, the Buyer must hold the Transferred Shares indefinitely unless they are
registered with the SEC and qualified by state authorities or an exemption from such registration and qualification requirements is available.
The Buyer further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various
requirements including the time and manner of sale, the holding period for the Transferred Shares, requirements relating to the Company
which are outside of the Buyer’s control, and which the Company is under no obligation and may not be able to satisfy.

 

4.
Representations and Warranties of Sellers. Each Seller represents and warrants to the Buyer and the Company, as of the Effective
Date, acknowledging that the Buyer is relying on such Seller’s representations and warranties in entering into this Agreement and
consummating the transactions contemplated hereunder, as follows:

 

4.1
Authorization. The Seller has all necessary power and authority to enter into and perform its obligations under this Agreement
and to transfer the applicable Transferred Shares under this Agreement, and this Agreement, when executed and delivered by the Seller,
shall constitute valid and legally binding obligations of the Seller, enforceable against the Seller in accordance with its terms except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors’ rights generally, and (b) as limited by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated
hereby, will not result in a violation of, or default under, any instrument, judgment, order, writ, decree or contract applicable to
the Seller, or an event that results in the creation of any lien, charge or encumbrance upon the applicable Transferred Shares.

 

    	3

     

    

 

4.2
Transfer for Own Account. The Seller is selling the applicable Transferred Shares for the Seller’s own account only
to the Buyer in a private sale and not with a view to, or for sale in connection with, a distribution of the applicable Transferred Shares
within the meaning of the 1933 Act.

 

4.3
No General Solicitation or General Advertising. At no time was the Buyer presented with or solicited by any publicly issued
or circulated newspaper, mail, radio, television, internet or other form of “general advertising” or “general solicitation”
within the meaning of Rule 502(c) under the 1933 Act in connection with the Transferred Shares.

 

4.4
No Broker-Dealer. The Seller has not effected this transfer of shares by or through a broker-dealer in any public offering.
The Seller agrees to indemnify and hold harmless the other parties to this Agreement from and against any loss, liability, damage, cost,
claim or expense incurred by reason of any brokerage, commission or finder’s fee alleged to be payable because of any act, omission
or statement of the indemnifying party.

 

4.5
Seller Tax Obligations. The Seller shall be solely responsible for paying any and all taxes and any related penalties, fines
and interest arising out of or related to the sale of the Transferred Shares contemplated hereby, including any capital gains and/or
income taxes arising from the sale of the Transferred Shares to the Buyer. The Seller acknowledges that the sale of the Transferred Shares
(and, if applicable, any exercise of options or warrants to acquire any Transferred Shares) may have immediate tax consequences. Furthermore,
the Seller agrees to indemnify and hold harmless the other parties to this Agreement from and against any loss, liability, damage, cost,
claim or expense incurred by such other parties by reason of any and all taxes of the Seller (including any withholding obligation) arising
from the sale of the Transferred Shares to the Buyer.

 

4.6
Title to Shares. Immediately prior to the Closing, the Seller is (i) the owner, beneficial and of record, of the total number
of shares of Subject Stock set forth in Schedule 1 for such Seller, and (ii) the owner, beneficial and of record, of all the Transferred
Shares to be sold by the Seller, and has valid marketable title to the Transferred Shares to be transferred to the Buyer under this Agreement,
free and clear of any pledge, lien, security interest, encumbrance, options, claim, charge or restrictions. At the Closing, the Seller’s
entire right, title and interest in and to the Transferred Shares shall be conveyed to the Buyer as set forth herein. The Seller has
the right and authority to sell lawfully the Transferred Shares to the Buyer pursuant to this Agreement and without any third party consent,
except such consents as have been obtained prior to the Closing or pursuant to this Agreement, and true and complete copies of which
have been provided to counsel to the Buyer.

 

4.7
Representation by Counsel. The Seller has been represented by its own counsel in connection with the transfer of the applicable
Transferred Shares or has knowingly chosen not to consult such counsel and understands the tax and accounting consequences associated
with the sale of the applicable Transferred Shares. The Seller acknowledges and agrees that it is not relying on any tax, accounting
or other advice from the Buyer, the Company or their respective counsel with respect to the Transferred Shares.

 

4.8 Company
Information. The Seller has sufficient information about the Company to reach an informed and knowledgeable decision to sell
the Transferred Shares and conducted its own analysis and its own due diligence with respect to the transaction, and has conducted
such analysis to whatever extent it considers appropriate to form a basis for its decision to sell the Transferred Shares. The
Seller acknowledges and agrees that the Purchase Price represents a negotiated price and may not reflect the fair market value of
the Transferred Shares and that neither the Company nor the Buyer has made any representation with regard to the fair market value
of the Transferred Shares and that the Seller is not relying upon the Company or the Buyer for any tax, investment or other advice.
The Seller freely accepts the risk inherent in its decision to sell the Transferred Shares.

 

    	4

     

    

 

4.9
No Continuing Rights. The Seller understands, acknowledges and agrees that the Seller shall have no rights with respect to
the Transferred Shares, as a stockholder of the Company or otherwise, with respect to any future sale, acquisition, merger, liquidation,
dissolution or other corporate event regarding the Company or its assets, or any public offering, tender offer or other offer to purchase
any of the Company’s shares of capital stock, whether by the Buyer or any other person or entity. The Seller further acknowledges
that the value attributed to the Transferred Shares or comparable shares of capital stock in any such transaction may be substantially
greater than the Purchase Price.

 

5.
Public Announcements. Except as required by any applicable law or regulatory requirement (including the United States securities
laws), no public announcement shall be made by any Person with regard to the transactions contemplated by this Agreement without the
prior written consent of Buyer. Buyer and the Company shall consult with each other before issuing any press release or making any other
public announcement with respect to this Agreement or the transactions contemplated hereby.

 

6.
Acknowledgments; No Reliance. Each Seller acknowledges and agrees that neither the Company, nor any of its stockholders (including
such Seller), officers, directors, employees or agents have (i) acted as an agent, finder or broker for the Seller or its respective
agents with respect to the offer, purchase or sale of the Transferred Shares or (ii) at any time had any duty to such Seller or their
respective agents to disclose any information relating to the Company, its business, or financial condition or relating to any other
matters in connection with the offer, purchase or sale of the Transferred Shares. In making the decision to sell the Transferred Shares,
such Seller is relying solely on the representations and warranties of the Buyer set forth in this Agreement (and not on any information
provided by the Company or its agents).

 

7.
Representations and Warranties of Company. Company represents and warrants to the Buyer, as of the Effective Date, acknowledging
that the Buyer is relying on Company’s representations and warranties in entering into this Agreement and consummating the transactions
contemplated hereunder, as follows:

 

7.1
Transferred Shares. The Transferred Shares have been duly authorized, are validly issued, fully paid and non-assessable, and
are owned of record and beneficially by each Seller as set forth in Schedule 1 hereto, free and clear of all liens, pledges, security
interests, charges, claims, encumbrances, agreements, options, voting trusts, proxies and other arrangements or restrictions of any kind
(“Encumbrances”). Upon consummation of the transactions contemplated by this Agreement, Buyer shall own the Transferred
Shares, free and clear of all Encumbrances. The execution, delivery and performance by each Seller of this Agreement do not conflict
with, violate or result in the breach of, or create any Encumbrance on the Transferred Shares pursuant to, any agreement, instrument,
order, judgment, decree, law or governmental regulation to which Seller is a party or is subject or by which the Transferred Shares are
bound. No governmental, administrative or other third party consents or approvals are required by or with respect to Company or any Seller
in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby.

 

7.2 Organization. The
Company is a corporation duly organized, validly existing, and in good standing under the laws of the state of Nevada and has full
corporate power and authority to own, operate, or lease the properties and assets now owned, operated, or leased by it and to carry
on its business as it has been and is currently conducted. The Company is duly licensed or qualified to do business and is in good
standing in each jurisdiction in which the properties owned or leased by it or the operation of its business as currently conducted
makes such licensing or qualification necessary.

 

    	5

     

    

 

7.3
Authority. The Company has full corporate power and authority to enter into this Agreement, to carry out its obligations hereunder,
and to consummate the transactions contemplated hereby. The execution and delivery by Company of this Agreement, the performance by the
Company of its obligations hereunder and thereunder, and the consummation by the Company of the transactions contemplated hereby and
thereby have been duly authorized by all requisite corporate action on the part of the Company. This Agreement constitutes legal, valid,
and binding obligations of the Company enforceable against the Company.

 

7.4
Capitalization. The authorized shares of the Company consist of 2,000,000,000 shares of common stock, $0.001 par value, of
which 807,047,948 shares are issued and outstanding. In accordance with Section 10 of this Agreement, the Buyer’s proportional
ownership of the Company’s voting capital stock shall not be decreased or diluted for the term outlined therein. There are no outstanding
or authorized options, warrants, convertible securities, stock appreciation, phantom stock, profit participation, or other rights, agreements,
or commitments relating to the shares of stock of the Company or obligating the Company to issue or sell any shares of stock of, or any
other interest in, the Company. Except for the Voting Agreement to be entered into pursuant to this Agreement, there are no voting trusts,
shareholder agreements, proxies, or other agreements in effect with respect to the voting or transfer of any of the Transferred Shares.

 

7.5
Compliance with Laws; Permits.

 

(a)
The Company has complied, and is now complying, with all statutes, laws, ordinances, regulations, rules, codes, treaties or other requirements
of any Governmental Authority (collectively, “Law”) applicable to it or its business, properties, or assets.

 

(b)
All permits, licenses, franchises, approvals, registrations, certificates, variances, and similar rights obtained, or required to be
obtained, from governmental authorities (collectively, “Permits”) that are required for the Company to conduct its
business have been obtained and are valid and in full force and effect. No event has occurred that would reasonably be expected to result
in the revocation or lapse of any such Permit.

 

(c)
The execution, delivery, and performance by Company of this Agreement and the consummation of the transactions contemplated hereby do
not and will not: (a) violate or conflict with any provision of the articles of incorporation, bylaws, or other governing documents of
Seller or the Company; (b) violate or conflict with any provision of any Laws or any order, writ, judgment, injunction, decree, determination,
penalty, or award entered by or with any Governmental Authority (“Governmental Order”) applicable to the Company;
(c) require the consent, notice, or filing with or other action by any Person or require any Permit, license, or Governmental Order;
(d) violate or conflict with, result in the acceleration of, or create in any party the right to accelerate, terminate, or modify any
contract, lease, deed, mortgage, license, instrument, note, indenture, joint venture, or any other agreement, commitment, or legally
binding arrangement, whether written or oral (collectively, “Contracts”), to which the Company is a party or by which
the Company is bound or to which any of their respective properties and assets are subject; or (e) result in the creation or imposition
of any Encumbrance on any properties or assets of the Company.

 

    	6

     

    

 

7.6
Applicable Laws.

 

(a)
There are no claims, actions, causes of action, demands, lawsuits, arbitrations, inquiries, audits, notices of violation, proceedings,
litigation, citations, summons, subpoenas, or investigations of any nature, whether at law or in equity (collectively, “Actions”)
pending or threatened against or by the Company: (i) relating to or affecting the Company or any of the Company’s properties or
assets; or (ii) that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. No event
has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

 

(b)
There are no outstanding, and the Company is in compliance with all, Governmental Orders against, relating to, or affecting the Company
or any of its properties or assets.

 

8.
Seller Releases of Company.

 

8.1
General Releases. Each Seller, on behalf of itself, its spouse or domestic partner, if any, its affiliates, and, if applicable,
its heirs, successors, beneficiaries and assigns and others who may claim through them, hereby waive and release and promise never to
assert any claims or causes of action, whether or not now known, against the Company, the Buyer or any of their respective predecessors,
successors, or past or present subsidiaries, parents, officers, directors, stockholders, agents, partners, members, managers, employees,
assigns, attorneys and advisors and any affiliates thereof (the “Released Parties”) from any and all actions, suits,
claims, demands, debts, sums of money, accounts, reckonings, bonds, bills, covenants, contracts, controversies, promises, judgments,
liabilities or obligations of any kind whatsoever in law or equity and causes of action of every kind and nature, or otherwise (including
claims for damages, costs, expenses, and attorneys’, brokers’ and accountants’ fees and expenses) arising out of or
related to events, facts, conditions or circumstances existing or arising on or prior to the Closing in connection with the Transferred
Shares (collectively, “Claims”), which the Seller can, shall or may have against the Released Parties, whether known
or unknown, suspected or unsuspected, unanticipated as well as anticipated and that now exist or may hereafter accrue (other than with
respect to an inaccuracy in or breach, violation or nonobservance of the representations, warranties, covenants or other agreements made
by such parties under this Agreement) including any Claims with respect to the valuation of the Transferred Shares, the transactions
contemplated by this Agreement, the Seller Excluded Information or the Buyer Excluded Information; provided, however, that this Section
8 does not apply to a claim by the Buyer against a Seller or by a Seller against the Buyer for breach of this Agreement.

 

8.2 Agreement
to Indemnify. Each Seller agrees to indemnify, defend and hold the Released Parties harmless from and against any and all
Claims arising out of or related to (i) the Transferred Shares being sold to the Buyer, including any such claims related to the
valuation thereof, or (ii) any inaccuracy in or breach, violation or nonobservance of the representations, warranties, covenants or
other agreements made by such Seller herein. Each Seller also agrees not to sue or otherwise participate in any action against any
of the Released Parties based on any Claims.

 

9.
Company Consent. The Company hereby consents to the transfers by the Sellers to the Buyer of the Transferred Shares and also
represents that it has obtained all necessary consents, waivers and authorizations of the Company, its Board of Directors and stockholders
under the Company’s Articles of Incorporation and Bylaws, each as amended and in effect on and as of the Effective Date, and under
any and all agreements or instruments of, between or among the Company and any of its stockholders, all as amended and in effect on and
as of the Effective Date.

 

    	7

     

    

 

10.
Restriction of Future Issuances by Company. From the date of this Agreement until the eight-month anniversary of the Closing,
the Company shall not issue any securities (including convertible securities) in a private or public offering or in any other way without
the Buyer’s prior written consent, which shall not be unreasonably withheld by Buyer, provided that: (i) in no event shall
Buyer’s proportional ownership of the Company’s voting capital stock be decreased or diluted from the date of this Agreement
until the eight-month anniversary of the Closing; and (ii) in no event shall the sum of Buyer’s shares and Sellers’ Remaining
Shares together represent less than 51% of the voting power of the Company from the date of this Agreement until the eight-month anniversary
of the Closing.

 

11.
Transfer Restrictions for Sellers’ Remaining Shares. From the date of this Agreement until the eight-month anniversary
of the Closing, each Seller agrees that such shares of Subject Stock that are not Transferred Shares (the “Remaining Shares”)
shall be subject to the transfer restrictions set forth in the Voting Agreement. Each Seller agrees that the voting rights for the Remaining
Shares shall be governed by the terms of the Voting Agreement.

 

12.
General Provisions.

 

12.1
Successors and Assigns; Assignment; Survival and Limitation of Liability. Except as otherwise provided in this Agreement,
this Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective
successors, assigns, heirs, executors, administrators and legal representatives. The representations, warranties and covenants contained
herein shall survive the execution and delivery of this Agreement and the Closing.

 

12.2
Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York, without
giving effect to that body of laws pertaining to conflict of laws which would result in the applicability of the law of any other state.

 

12.3
Choice of Forum. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated
hereby may be instituted in the federal courts of the United States or the courts of the State of New York in each case located in the
City of New York and County of New York, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such
suit, action or proceeding. Service of process, summons, notice or other document by mail to such party’s address set forth herein
shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive
and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum.

 

12.4
Further Assurances. The parties shall use their respective best efforts to consummate the transactions contemplated hereby.
The parties agree to execute such further documents and instruments and to take such further actions as may be reasonably necessary to
carry out the purposes and intent of this Agreement.

 

12.5
Specific Enforcement. Notwithstanding anything to the contrary set forth herein, it is agreed and understood that monetary
damages would not adequately compensate an injured party hereto for the breach of this Agreement by any other party hereto, that this
Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of
a temporary or permanent injunction or restraining order. Further, each party hereto waives any claim or defense that there is an adequate
remedy at law for such breach or threatened breach.

 

    	8

     

    

 

12.6
Entire Agreement. This Agreement constitutes the entire agreement and understanding of the parties with respect to the subject
matter of this Agreement, and supersedes all prior understandings and agreements, whether oral or written, between or among the parties
hereto with respect to the specific subject matter hereof.

 

12.7
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
portable document format (“PDF”) or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered
and be valid and effective for all purposes.

 

12.8
Severability. If any provision of this Agreement is determined by any court or arbitrator of competent jurisdiction to be
invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of
the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder
of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable)
never been contained in this Agreement.

 

12.9
Titles and Subtitles; Interpretation. The titles and subtitles used in this Agreement are for convenience only and are not
to be considered in construing or interpreting this Agreement. Where the context requires, the use of a pronoun of one gender or the
neuter is to be deemed to include a pronoun of the appropriate gender. The words “include,” “includes,” “including”,
“such as”, “for example” and words or phrases of similar intent shall not be deemed to be terms of limitation,
but rather shall be deemed to be followed by the words “without limitation” or words of similar effect, and the word “or”
shall not be determined to be exclusive, in each case, unless the context otherwise requires.

 

12.10
Notices. All notices and other communications given or made pursuant to this Agreement must be in writing and will be deemed
to have been given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by
electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid or
(d) one business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery,
with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on the
respective signature page hereto or to such email address or address as subsequently modified by written notice given in accordance with
this Subsection. If notice is given to Buyer, a copy (which shall not constitute notice to Buyer) shall also be sent to Dentons US LLP,
counsel for the Company, 1221 Avenue of the Americas, New York, NY 10020-1089, Attn: Eric Berlin (eric.berlin@dentons.com) and
Walter Van Dorn (walter.vandorn@dentons.com). For electronic mail notice to be effective, an electronic mail address must be provided
for notice purposes and the electronic mail must be confirmed as received personally by the recipient by non-automated response electronic
mail or the sender must dispatch a copy of the notice within one business day thereafter overnight courier in accordance with clause
(d).

 

12.11 Amendment
and Waivers. This Agreement may be amended only by a written agreement of the Buyer, the Company and the Sellers. No
amendment, waiver, or modification of any obligation under this Agreement will be enforceable unless set forth in a writing signed
by the party against which enforcement is sought. No delay or failure to require performance of any provision of this Agreement
shall constitute a waiver of that provision as to that or any other instance. No waiver granted under this Agreement as to
any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it
constitute the waiver of any performance other than the actual performance specifically waived.

 

[Remainder
of Page Left Blank Intentionally – Signature Follows]

 

    	9

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Secondary Stock Purchase Agreement and Release as of the date first above written.

 

	 	BUYER:
	 	 
	 	BRIGHT
    GREEN CORPORATION
	 	 
	 	 	/s/ Terry
    Rafih
	 	Name:
    	Terry
    Rafih
	 	Title:	

Chairman &CEO

	 	 	 
	 	Address:

	 	 	 
	 	Email Address:	Trafih@brightgreen.us

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Secondary Stock Purchase Agreement and Release as of the date first above written.

 

	 	SELLERS:
	 	 
	 	PHYTO
	 	 
	 	By: 	/s/ Colin
    Stott
	 	Name:	Colin Stott
	 	Title:	Chief Executive Officer

                                                                              Phytotherapeutix Holdings Ltd

	 	Address:	Bretton House

                                                                              Bell Meadow Business Park

                                                                              Park Lane, Pulford

                                                                              Chester, CH4 9EP, UK

	 	Email Address:	cstott@phytptherapeutix.com
	 	 
	 	EQUIPPED
	 	 
	 	By: 	/s/ Mr Dominic Schiller
	 	Name:	Mr Dominic Schiller
	 	Title:	Director
	 	Address:	106 Birkenhead Road

                                                                              Meols

                                                                              Wirral UK

	 	Email Address:	ds@equipped4.com
	 	 
	 	TPR
	 	 
	 	By: 	/s/ Timothy Paul Rogers
	 	Name:	Timothy Paul Rogers
	 	Title:	Executive Chairman
	 	Address:	Bell Meadow Business Park, Bretton House, Chester CH4 9EP
	 	Email Address:	Tim.rogers29@me.com

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Secondary Stock Purchase Agreement and Release as of the date first above written.

 

	 	COMPANY:
	 	 
	 	ALTEROLA
    BIOTECH INC.
	 	 
	 	By: 	/s/ Timothy
    Rogers
	 	Name:	Timothy Rogers
	 	Title:	Executive Chairman
	 	Address:	47 Hamilton Square

                                                                              Birkenhead,

                                                                              Merseyside

                                                                              CH41 5AR

                                                                              United Kingdom

	 	Email Address:	tr@alterolabio.com

 

    	 

     

    

 

SCHEDULE
1

 

	Name of Seller	 	Class of

                                                                                Subject

                                                                                Stock
	 	Total Number of

                                                                                Shares of Subject

                                                                                Stock Owned
	 	 	Number of

                                                                                 Transferred Shares

                                                                                 Sold to Buyer

                                                                                 Pursuant to this
 Agreement
	 	 	Purchase Price (USD)	 
	Phytotherapeutix Holdings Ltd.	 	Common Stock	 	 	180,000,000	 	 	 	67,253,994	 	 	$	1,333,333	 
	Equipped4 Holdings Limited	 	Common Stock	 	 	180,000,000	 	 	 	67,253,994	 	 	$	1,333,333	 
	TPR Global Limited	 	Common Stock	 	 	180,000,000	 	 	 	67,253,994	 	 	$	1,333,333	 

 

Payment
Schedule

 

	Payment Date	 	Payment Amount (USD)	 	 	Allocation of Payment Amount for Each Seller	 
	Closing	 	$	2,350,000.00	 	 	$	783.333.33	 
	Within 60 days following the Closing	 	$	1,000,000.00	 	 	$	333,333.33	 
	Within 90 days following the Closing	 	$	650,000.00	 	 	$	216,666.67	 

 

    	 

     

    

 

EXHIBIT
A

 

 LOAN AGREEMENT

 

    	 

     

    

 

FORM
OF LOAN AGREEMENT

 

 

THIS
LOAN AGREEMENT is made on {                } by and between:

 

	 	(1)	Alterola Biotech
Inc., a corporation organized and existing under the laws of Nevada having its corporate seat in 47 Hamilton Square, Birkenhead, Merseyside
CH41 5AR (hereinafter referred to as the “Borrower”);

 

and

 

	 	(2)	[name of company],
a [type of company] organized and existing under the laws of United Kingdom having its corporate seat in [registered address
of the company head office] and registered under number [trade register number] (hereinafter referred to as the “Lender”)

 

(Borrower
and Lender are hereinafter jointly referred to as “Parties” and each one individually as “Party”).

 

WHEREAS:

 

	(A)	The Borrower conducts
a business in the field of Pharmaceutical Development.

 

	(B)	The Borrower is
in need of funding in order to finance its business and the Lender is willing to provide the Borrower with a loan subject to the terms
and conditions laid down by this agreement (hereinafter referred to as the “Agreement”).

 

	(C)	This Agreement
is one of a series of loan agreements entered or to be entered into by the Borrower with lenders with identical terms and in the same
form as set forth herein, except that the loan amount and date of issuance may differ.

 

    	 

     

    

 

THE
PARTIES HAVE AGREED AS FOLLOWS:

 

	1.	DEFINITIONS

 

	 	1.1.	Unless otherwise
stated or defined, the following terms shall have the following meaning for the purposes of this Agreement:

 

	 	$	means United States Dollars being the lawful currency of the United States of America;

 

	 	
    Event of Default:
	
    the following situations
shall result in an event of default:

     

    

	 	 	if the Borrower fails
                                                                              to properly or timely perform one or more
                                                                              of its obligations pursuant to this Agreement vis- à-vis the Lender and – following being summoned and given a term of
                                                                              at least 7 days to remedy such failure – has not remedied such failure;

     

    if
    the Borrower is declared bankrupt, files a petition for the suspension of payment, files for its own bankruptcy or is subject to
    other insolvency proceedings; or in the event an attachment is levied on (which is not withdrawn within 20 days of it being imposed)
    or the transfer of a – at the sole determination of the Lender – material part of the assets of the Borrower.

	 	 	 
	 	Lender
    Majority:	one
    or more lenders that alone or together represent the majority of the outstanding loan amounts of all Loan Agreements at the time
    the majority is formed;
	 	 	 
	 	Loan
    Agreements:	the
    loan agreements entered or to be entered into by the Borrower with lenders with identical terms and in the same form as set forth
    herein, except that the loan amount and date of issuance may differ;
	 	 	 
	 	Maturity
    Date:	the
    date eight (8) months following the date of signing of the Secondary Stock Purchase Agreement and Release entered into between the
    Borrower, Lender and Bright Green Corporation dated 03 October 2022;
	 	 	 
	 	Qualified
    Financing:	issue
                                                                              of Shares of the Borrower, against payment of an amount of at least $4,000,000, in one or more installments, or issue of convertible
                                                                              securities of Borrower convertible into Shares, against payment of an amount of at least $4,000,000, in one or more installments; or
                                                                              sale or acquisition or change in control of the Borrower

	 	 	 
	 	Shares:	shares
    of capital stock of the Borrower.

 

    	Exh. A-2

     

    

 

	2.	THE LOAN

 

	 	2.1.	The Lender hereby
agrees to grant the Borrower a loan in the amount of [INSTALLMENT PROCEED AMOUNT] US Dollars ($[INSTALLMENT PROCEED AMOUNT]). The Borrower
may draw down funds up to and including $[INSTALLMENT PROCEED AMOUNT] (hereinafter referred to as the “Loan”) on a
scheduled basis as required by the Borrower. Such drawdown shall be subject to receipt of funds in accordance with the schedule of payment
as outlined in the Secondary Stock Purchase Agreement and Release between the Borrower, Lender and Bright Green Corporation.

 

	 	2.2.	The Lender shall
make Loan monies available to the Borrower within five business (5) days after the signing of this Agreement by payment into the Borrower’s
bank account as specified for that purpose by the Borrower.

 

	3.	INTEREST

 

	 	3.1.	Interest shall
be due on the outstanding sum of the principal amount and interest accrued thereon at a rate of 0.75% per annum.

 

	 	3.2.	The interest shall
accrue on a monthly basis as per the date of signing of this Agreement and shall be calculated on the basis of the actual number of days
elapsed and a year of 365 days.

 

	 	3.3.	Interest shall
only become due upon repayment of the Loan.

 

	4.	REPAYMENT

 

			The Loan is repayable in
                                                                                                                                                             full together with all interest outstanding on the earlier of: (a) the occurrence of a Qualified Financing, which exceeds an amount
                                                                                                                                                             of Four Million US Dollars ($4,000,000) PROVIDED THAT (i) the Lender requests such repayment by notice to the Borrower within 20
                                                                                                                                                             Business Days of such occurrence and (ii) such repayment would not constitute a threat to the financial health of the Borrower in a
                                                                                                                                                             way that it would trigger an Event of Default; (b) the Maturity Date; and (c) the occurrence of an Event of Default.

 

	5.	WARRANTIES

 

	 	5.1.	In connection with
the transactions provided for under this Agreement, the Borrower hereby represents and warrants to the Lender that:

 

	 	5.1.1.	The Borrower is
a corporation duly organized and validly existing under the laws of Nevada and having all requisite corporate power and authority to
carry out its business as now conducted;
	 	 	 
	 	5.1.2.	all corporate actions
have been taken on the part of the Borrower, its directors and shareholders, which are necessary for the authorization, execution and
issuance of this Loan, which shall constitute a valid and legally binding obligation on the side of the Borrower and therefore enforceable
against the latter in accordance with its terms;

 

    	Exh. A-3

     

    

 

	 	5.1.3.	the Borrower has
provided to the Lender any information which is material to a lender granting a loan, and that this information is true, accurate and
not misleading; and
	 	 	 
	 	5.1.4.	all intellectual
property rights which are, or are likely to be, material to the business of the Borrower are, comprehensively and free of encumbrances,
vested in the Borrower.

 

	6.	COVENANTS

 

	 	6.1.	As long as the
Borrower has any outstanding obligations vis-a-vis the Lender pursuant to this Agreement, the Borrower shall not directly or indirectly
take any of the following actions without the prior written consent (including via e-mail) of the Lender Majority:

 

	 	6.1.1.	pay or declare
any dividend or make any distribution on Shares or redeem any Shares in the share capital of the Borrower;
	 	 	 
	 	6.1.2.	obtain any loans;
and
	 	 	 
	 	6.1.3.	grant a right to
pledge on, sell or otherwise transfer or encumber a material part of the assets of Borrower.

 

	 	6.2.	As long as the
Borrower has any outstanding obligations vis-a-vis the Lender pursuant to this Agreement, the Borrower shall:

 

	 	6.2.1.	provide the Lender
with a copy of its financial statements, including a balance sheet, profit- and-loss account and explanatory notes in respect of the
said financial year, as soon as these are available, and in any event within 6 months following the end of the financial year;
	 	 	 
	 	6.2.2.	inform the Lender
immediately once an amendment of its Articles of Incorporation has been enacted; and
	 	 	 
	 	6.2.3.	upon request by
the Lender, provide the Lender with all information the Lender reasonably requires from time to time.

 

    	Exh. A-4

     

    

 

	7.	CONFIDENTIALITY

 

	 	7.1.	All Confidential
Information concerning the Borrower and each of the Parties, disclosed by one Party to the other Party (whether oral, written or embodied
in any other form) together with this Agreement’s existence and its terms, are confidential and will only be disclosed by a Party:

 

	 	i)	After having obtained
the written consent of the other Party, such consent not unreasonably withheld;
	 	 	 
	 	ii)	On a confidential
basis to an officer, employee, or professional adviser, for the purpose and within the scope of the duties of the latter;
	 	 	 
	 	iii)	As required by
applicable law or any court or governmental agency, after consulting with the other Party to the extent reasonably possible about the
form and content of the disclosure; or
	 	 	 
	 	iv)	As required in
connection with the implementation and enforcement of this Agreement.

 

7.
MISCELLANEOUS

 

This
Agreement, the documents referred to or incorporated in it, and the agreements resulting therefrom constitute the whole agreement between
the Parties relating to the Loan, and supersede any prior arrangements, understandings or agreements between them, oral or written, explicit
or implied, in relation to the subject-matter hereby covered.

 

If
any (or part of any) provision of this Agreement is found to be invalid, unenforceable or illegal by a competent court, the rest of the
provisions of this Agreement shall remain in force. If any invalid, unenforceable or illegal provision would be valid, enforceable or
legal if some part of it were deleted or modified, that provision shall apply with whatever modification is necessary to give full effect
to the intention of the Parties.

 

Any
notice to be given by a Party pursuant to this Agreement shall be in writing (including by e-mail) and shall be sent to the address of
the applicable Party as set out in the preamble to this Agreement. Each Party may change its address by giving notice to the other Party.

 

This
Agreement may only be amended by agreement of both Parties in writing.

 

This
Agreement shall be governed by the Laws of England and Wales. Any disputes arising from or in connection with this Agreement shall exclusively
be referred to the competent court in England and Wales.

 

This
Agreement was signed on the date first written above.

 

	Alterola Biotech
    Inc.	 	[name of company]
	 	 	 
	Represented by:	 	Represented by:
	 	 	 
	[name of
    representative]	 	[name of
    representative]
	 	 	 
	 	 	 
	 	 	 
	{XX October 2022}	 	 

 

    	Exh. A-5

     

    

 

EXHIBIT
B

 

ASSIGNMENT
SEPARATE FROM CERTIFICATE

 

FOR
VALUE RECEIVED and pursuant to that certain Secondary Stock Purchase Agreement and Release by and among Phytotherapeutix Holdings Ltd.,
a United Kingdom entity (“Phyto”), Equipped4 Holdings Limited, a United Kingdom entity (“Equipped”),
TPR Global Limited, a United Kingdom entity (“TPR”) (Phyto, Equipped and TPR, each, a “Seller”
and collectively, the “Sellers”), Bright Green Corporation, a Delaware corporation (the “Buyer”)
and Alterola Biotech Inc., a Nevada corporation (the “Company”), dated as of the date hereof, the undersigned Seller
hereby sells, assigns and transfers unto the Buyer the number, class and series of issued and outstanding shares of capital stock of
the Company listed as the Seller’s “Transferred Shares” on Schedule 1 hereto, standing in the name of the Seller
on the Company’s books, and does hereby irrevocably constitute and appoint the Company to transfer said stock on the books of the
Company with full power of substitution in the premises.

 

Dated:
October 03, 2022

 

		Seller

 

    	Exh. B-1

     

    

 

EXHIBIT
C

 

VOTING
AGREEMENT

 

    	 

     

    

 

VOTING
AGREEMENT

 

This
VOTING AGREEMENT (this “Agreement”), dated as of October 03, 2022, is by and between Bright Green
Corporation, a Delaware corporation (the “Buyer”), Phytotherapeutix Holdings Ltd., a United Kingdom entity
(“Phyto”), Equipped4 Holdings Limited, a United Kingdom entity (“Equipped”) and
TPR Global Limited, a United Kingdom entity (“TPR”) (Phyto, Equipped and TPR, each, a
“Stockholder,” and, collectively, the “Stockholders”) of Alterola Biotech Inc.,
a Nevada corporation (the “Company”).

 

A.
Buyer, Stockholders and Company are party to that certain Secondary Stock Purchase Agreement and Release, dated as of the date hereof
(the “Secondary SPA”), whereby Sellers shall sell certain shares of common stock of the Company to Buyer; and

 

B.
Each Stockholder is the Beneficial Owner (as defined below) of, and has the sole right to vote and dispose of, that number of each class
of the issued and outstanding capital stock of the Company (the “Company Shares”) set forth opposite such Stockholder’s
name on Schedule A hereto, which shall be the same shares as those defined as the “Remaining Shares” in the Secondary
SPA; and

 

C.
Concurrently with the entry by the Buyer, Stockholders and Company into the Secondary SPA, and as a condition and inducement to the willingness
of the Buyer to enter into the Secondary SPA and incur the obligations set forth therein, Buyer has required that the Stockholders enter
into this Agreement.

 

Accordingly,
and in consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained herein, the parties
hereto, intending to be legally bound, hereby agree as follows:

 

ARTICLE
1.

DEFINITIONS

 

For
purposes of this Agreement:

 

“Affiliate”
means, with respect to any specified Person, a Person who, at the time of determination, directly or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, such specified Person. For purposes of this Agreement, with respect to
a Stockholder, “Affiliate” does not include the Company and the Persons that directly, or indirectly through
one or more intermediaries, are controlled by the Company. For the avoidance of doubt, no officer or director of the Company will be
deemed an Affiliate of another officer or director of the Company by virtue of his or her status as an officer or director of the Company.

 

“Beneficial
Owner” with respect to any securities means a Person that has Beneficial Ownership of such securities.

 

“Beneficially
Owned” or “Beneficial Ownership” with respect to any securities means having beneficial ownership
of such securities (as determined pursuant to Rule 13d-3 under the Exchange Act, disregarding the phrase “within 60 days”
in paragraph (d)(1)(i) thereof), including pursuant to any agreement, arrangement or understanding, whether or not in writing. Without
duplicative counting of the same securities, securities Beneficially Owned by a Person include securities Beneficially Owned by (i) all
Affiliates of such Person, and (ii) all other Persons with whom such Person would constitute a “group” within the meaning
of Section 13(d) of the Exchange Act and the rules promulgated thereunder.

 

    	 

     

    

 

“Subject
Shares” means, with respect to a Stockholder, without duplication, (i) the Company Shares Beneficially Owned by such Stockholder
on the date hereof as described on Schedule A, (ii) any additional Company Shares Beneficially Owned or acquired by such Stockholder,
including those over which such Stockholder acquires Beneficial Ownership from and after the date hereof, whether pursuant to existing
stock option agreements, warrants or otherwise, and (iii) any securities converted, exchanged or reclassified into Company Shares. Without
limiting the other provisions of this Agreement, in the event that the Company changes the number of Company Shares issued and outstanding
prior to the Termination Date as a result of a reclassification, stock split (including a reverse stock split), stock dividend or distribution,
combination, recapitalization, subdivision, or other similar transaction, the number of Subject Shares subject to this Agreement will
be equitably adjusted to reflect such change.

 

“Transfer”
means, with respect to a security, the sale, transfer, pledge, hypothecation, encumbrance, assignment or disposition of such security
or the Beneficial Ownership thereof, whether by operation of Law or otherwise, and each option, agreement, arrangement or understanding,
whether or not in writing, to effect any of the foregoing. As a verb, “Transfer” has a correlative meaning.

 

“Person”
means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization,
trust, association or other entity.

 

ARTICLE
2.

COVENANTS
OF STOCKHOLDERS

 

2.1
Irrevocable Proxy. Concurrently with the execution of this Agreement, each Stockholder agrees to deliver to Buyer a proxy in the
form attached hereto as Exhibit A (the “Proxy”), which will be irrevocable to the extent provided therein,
with respect to the Subject Shares referred to therein.

 

2.2
Agreement to Vote.

 

(a)
At each and every meeting of the stockholders of the Company held prior to the Termination Date, however called, and at every
adjournment or postponement thereof prior to the Termination Date, or in connection with each and every written consent of, or any
other action by, the stockholders of the Company given or solicited prior to the Termination Date, each Stockholder will vote, grant
its proxy or provide a consent with respect to, or shall cause the holder of record on any applicable record date to vote, grant its
proxy or provide a consent with respect to, all of the Subject Shares entitled to vote or to consent thereon (i) in favor of the
adoption of an agreement to effect Buyer’s acquisition of the Company or the Company’s merger into Buyer or a subsidiary
of Buyer, as the case may be (a “Merger Agreement”) and Buyer’s acquisition of the Company or the
Company’s merger into Buyer or a subsidiary of Buyer, as the case may be (the “Merger”), at
Buyer’s sole discretion and (ii) against any amendment of the Company’s certificate of incorporation or bylaws or any
other proposal or transaction involving the Company, the effect of which amendment or other proposal or transaction is to delay,
impair, prevent or nullify the Merger or the transactions contemplated by the Merger Agreement or change in any manner the voting
rights of any capital stock of the Company, and against any other action or agreement that would result in a breach in any material
respect of any covenant, representation or warranty or any other obligation or agreement of the Company or its stockholders under
the Merger Agreement. Notwithstanding any other provision of this Agreement, each Stockholder’s obligations under this Section
2.2(a) shall not extend to any modification or amendment to the Merger Agreement unless such Stockholder otherwise agrees in a
subsequent writing.

 

(b)
No Stockholder will enter into any agreement with any Person (other than Buyer) prior to the Termination Date (with respect to
periods prior to or after the Termination Date) directly or indirectly to vote, consent, grant any proxy or give instructions with
respect to the voting of, the Subject Shares in respect of the matters described in Section 2.2(a) hereof, or the effect of
which would be inconsistent with or violate any provision contained in this Section 2.2. Any vote or consent (or withholding
of consent) by any Stockholder that is not in accordance with this Section 2.2 will be considered null and void.

 

    	Exh. C-2

     

    

 

2.3
Revocation of Proxies; Cooperation. Each Stockholder agrees as follows:

 

(a)
Such Stockholder hereby represents and warrants that any proxies heretofore given in respect of the Subject Shares with respect to the
matters described in Section 2.2(a) hereof are not irrevocable, and such Stockholder hereby revokes any and all prior proxies
with respect to such Subject Shares as they relate to such matters. Prior to the Termination Date, such Stockholder will not directly
or indirectly grant any proxies or powers of attorney with respect to the matters set forth in Section 2.2(a) hereof (other than
to Buyer), deposit any of the Subject Shares or enter into a voting agreement (other than this Agreement) with respect to any of the
Subject Shares relating to any matter described in Section 2.2(a).

 

(b)
Such Stockholder will provide any information reasonably requested by the Company or Buyer for any regulatory application or filing sought
for such transactions.

 

2.4
No Transfer of Subject Shares; Publicity. Each Stockholder agrees that:

 

(a)
It (i) will not Transfer or agree to Transfer any of the Subject Shares or, with respect to any matter described in Section
2.2(a), grant any proxy or power-of-attorney with respect to any of the Subject Shares, (ii) will take all action reasonably
necessary to prevent creditors in respect of any pledge of the Subject Shares from exercising their rights under such pledge, and
(iii) will not take any action that would make in a material respect any of its representations or warranties contained herein
untrue or incorrect or would have the effect of preventing or disabling such Stockholder from performing any of its material
obligations hereunder; provided, however, that Stockholder may transfer the Subject Shares (1) to Affiliates (including, for
the avoidance of doubt, if Stockholder is a corporation, partnership, limited liability company, investment fund, trust or other
business entity, such investment funds or other business entities controlled or managed by, or that controls or manages, or under
common management with, the Stockholder) or charitable organizations, (2) if Stockholder is an individual, to any member of
Stockholder’s immediate family, or to a trust for the benefit of Stockholder or any member of Stockholder’s immediate
family for estate planning purposes or for the purposes of personal tax planning, or upon the death of Stockholder, by will or
intestacy, (3) if Stockholder is a corporation, partnership, limited liability company, investment fund or other business entity, as
part of a disposition, transfer or distribution by the Stockholder to its equity holders, (4) if the Stockholder is a trust, to a
trustor or beneficiary of the trust; (5) to a nominee or custodian of a Person or entity to whom a disposition or transfer would be
permissible under this clause, or (6) to the Company in an exchange of the Subject Shares in a Company Permitted Reorganization (any
such transferee permitted under clauses (1) through (5), a “Permitted Transferee”); provided, further, that
any such Transfer permitted under clauses (1) through (5) shall be permitted only if, as a precondition to such Transfer, the
Permitted Transferee agrees in writing to be bound by all of the terms of this Agreement.

 

(b)
Unless required by applicable Law or permitted by the Secondary SPA or the Merger Agreement, such Stockholder will not, and will not
authorize or direct any of its Affiliates, Representatives, employees or agents to, make any press release or public announcement with
respect to this Agreement, the Secondary SPA or the Merger Agreement or the transactions contemplated hereby or thereby, without the
prior written consent of Buyer in each instance.

 

    	Exh. C-3

     

    

 

ARTICLE
3.

REPRESENTATIONS,
WARRANTIES AND ADDITIONAL COVENANTS OF

STOCKHOLDERS

 

Each
Stockholder represents, warrants and covenants to Buyer that:

 

3.1
Ownership. Such Stockholder is the sole Beneficial Owner or the record owner of the Subject Shares identified opposite such Stockholder’s
name on Schedule A, and such Subject Shares constitute all of the capital stock of the Company Beneficially Owned by such Stockholder
immediately following the Stockholders’ sale of the Transferred Shares (as defined in the Secondary SPA) to the Buyer pursuant
to the Secondary SPA. Such Stockholder has good and valid title to all of the Subject Shares, free and clear of all Liens, claims, options,
proxies, voting agreements and security interests and has the sole right to such Subject Shares, and there are no restrictions on rights
of disposition or other Liens pertaining to such Subject Shares. None of the Subject Shares is subject to any voting trust or other contract
with respect to the voting thereof, and no proxy, power of attorney or other authorization has been granted with respect to any of such
Subject Shares.

 

3.2
Authority and Non-Contravention.

 

(a)
Such Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform its obligations hereunder and
to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by such Stockholder and the consummation
by such Stockholder of the transactions contemplated hereby have been duly and validly authorized by all necessary action, and no other
proceedings on the part of such Stockholder are necessary to authorize this Agreement or to consummate the transactions contemplated
hereby.

 

(b)
This Agreement has been duly and validly executed and delivered by such Stockholder and, assuming due authorization, execution and delivery
of this Agreement by Buyer, constitutes the legal, valid and binding obligation of such Stockholder, enforceable against such Stockholder
in accordance with its terms except (i) to the extent limited by applicable bankruptcy, insolvency or similar laws affecting creditors’
rights and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses
and to the discretion of the court before which any proceeding therefor may be brought.

 

(c)
Such Stockholder is not nor will it be required to make any filing with or give any notice to, or to obtain any consent from, any Person
in connection with the execution, delivery or performance of this Agreement or obtain any permit or approval from any Governmental Entity
for any of the transactions contemplated hereby, except to the extent required by Section 13 or Section 16 of the Exchange Act and the
rules promulgated thereunder.

 

(d)
Neither the execution and delivery of this Agreement by such Stockholder nor the consummation of the transactions contemplated hereby
will directly or indirectly (whether with notice or lapse of time or both) (i) conflict with, result in any violation of or constitute
a default by such Stockholder under any mortgage, bond, indenture, agreement, instrument or obligation to which such Stockholder is a
party or by which it or any of the Subject Shares are bound, or violate any permit of any Governmental Entity, or any applicable Law
to which such Stockholder, or any of the Subject Shares, may be subject, or violate any organizational documents of such Stockholder
or (ii) result in the imposition or creation of any Lien upon or with respect to any of the Subject Shares; except, in each case, for
conflicts, violations, defaults or Liens that would not individually or in the aggregate be reasonably expected to prevent or materially
impair or delay the performance by such Stockholder of its obligations hereunder.

 

(e)
Such Stockholder has sole voting power and sole power to issue instructions with respect to the matters set forth in Article II hereof
and sole power to agree to all of the matters set forth in this Agreement, in each case with respect to all of the Subject Shares, with
no limitations, qualifications or restrictions on such rights.

 

    	Exh. C-4

     

    

 

3.3
Reliance. Each Stockholder understands and acknowledges that Buyer is entering into the Secondary SPA in reliance upon the Stockholders’
execution, delivery and performance of this Agreement.

 

ARTICLE
4.

REPRESENTATIONS,
WARRANTIES AND COVENANTS OF BUYER

 

Buyer
represents, warrants and covenants to Stockholders that:

 

(a)
Buyer has all necessary corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder.
The execution and delivery by Buyer of this Agreement and the consummation by Buyer of the transactions contemplated hereby have been
duly and validly authorized by Buyer and no other corporate proceedings on the part of Buyer are necessary to authorize this Agreement
or to consummate the transactions contemplated hereby.

 

(b)
This Agreement has been duly and validly executed and delivered by Buyer and, assuming due authorization, execution and delivery of this
Agreement by the Stockholders, constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance
with its terms, except (i) to the extent limited by applicable bankruptcy, insolvency or similar laws affecting creditors’ rights
and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and
to the discretion of the court before which any proceeding therefor may be brought.

 

ARTICLE
5.

DISSENTERS’
RIGHTS

 

5.1
Each Stockholder hereby waives and agrees not to exercise any rights of appraisal or any dissenters’ rights that Stockholder may
have (whether under applicable Law or otherwise) or could potentially have or acquire in connection with the Merger.

 

ARTICLE
6.

TERM
AND TERMINATION

 

6.1
This Agreement will become effective upon its execution by the Stockholders and Buyer. This Agreement will terminate upon the
earliest of (a) eight months from the date of this Agreement, or (b) written notice by Buyer to the Stockholders of the termination
of this Agreement (the date of the earliest of the events described in clauses (a) and (b), the “Termination
Date”). Notwithstanding the foregoing, Article VII of this Agreement shall survive any termination hereof.

 

    	Exh. C-5

     

    

 

ARTICLE
7.

GENERAL
PROVISIONS

 

7.1 Action
in Stockholder Capacity Only. Each Stockholder is entering into this Agreement solely in such Stockholder’s capacity as a
record holder or Beneficial Owner, as applicable, of the Subject Shares and not in such Stockholder’s capacity as a director
or officer of the Company.

 

7.2
No Ownership Interest. Nothing contained in this Agreement will be deemed to vest in Buyer or any of its Affiliates any direct
or indirect ownership or incidents of ownership of or with respect to the Subject Shares. All rights, ownership and economic benefits
of and relating to the Subject Shares will remain and belong to the Stockholders, and neither Buyer nor any of its Affiliates will have
any authority to manage, direct, superintend, restrict, regulate, govern or administer any of the policies or operations of the Company
or exercise any power or authority to direct any Stockholder in the voting of any of the Subject Shares, except as otherwise expressly
provided herein or in the Merger Agreement.

 

7.3
Notices. All notices and other communications hereunder shall be in writing (including email or similar writing) and must be given:

 

If
to Buyer, to the address and email address set forth for the Buyer on Buyer’s signature page hereto,

 

with
a copy (which will not constitute notice) to:

 

	 	Dentons US LLP
	 	1221 Avenue of the Americas
	 	New York, NY 10020
	 	Attention:	 Eric Berlin
	 	 	Walter Van Dorn
	 	Email:	eric.berlin@dentons.com
	 	 	walter.vandorn@dentons.com

 

If
to any Stockholder, to such Stockholder at its address or email address set forth on Schedule A,

 

or
such other physical address or email address as a party may hereafter specify for the purpose by notice to the other parties hereto.
Each notice, consent, waiver or other communication under this Agreement will be effective only (i) if given by email, when the email
is transmitted to the email address specified in this Section 7.3 or (ii) if given by overnight courier or personal delivery when
delivered at the physical address specified in this Section 7.3.

 

7.4 Further
Actions. Upon the request of any party to this Agreement, the other party will (a) furnish to the requesting party any
additional information, (b) execute and deliver, at their own expense, any other documents and (c) take any other actions as the
requesting party may reasonably require to more effectively carry out the intent of this Agreement. Each Stockholder hereby agrees
that Buyer may publish and disclose in any filing made by the Buyer with the Securities and Exchange Commission
(“SEC”) relating to the Merger Agreement or the transactions contemplated thereby (including all documents
and schedules filed with the SEC) such Stockholder’s identity and ownership of Subject Shares and the nature of such
Stockholder’s commitments, arrangements, and understandings under this Agreement and may further file this Agreement as an
exhibit to any filing made by the Buyer with the SEC relating to the Merger Agreement or the transactions contemplated
thereby.

 

7.5 Entire
Agreement and Modification. This Agreement, the Proxy, the Secondary SPA and any other documents delivered by the parties in
connection herewith constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all
prior agreements and understandings, both written and oral, between the parties with respect to its subject matter and constitute
(along with the documents delivered pursuant to this Agreement) a complete and exclusive statement of the terms of the agreement
between the parties with respect to its subject matter. This Agreement may not be amended, supplemented or otherwise modified except
by a written document executed by the party against whose interest the modification will operate. The parties will not enter into
any other agreement inconsistent with the terms and conditions of this Agreement, the Proxy or the Secondary SPA, or that addresses
any of the subject matters addressed in this Agreement, the Proxy or the Secondary SPA.

 

    	Exh. C-6

     

    

 

7.6
Drafting and Representation. The parties agree that the terms and language of this Agreement were the result of negotiations between
the parties and, as a result, there will be no presumption that any ambiguities in this Agreement will be resolved against any party.
Any controversy over construction of this Agreement will be decided without regard to events of authorship or negotiation.

 

7.7
Severability. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction will, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without affecting the validity or enforceability of the remaining
provisions hereof. Any such prohibition or unenforceability in any jurisdiction will not invalidate or render unenforceable such provision
in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision will be interpreted to
be only so broad as is enforceable.

 

7.8
No Third-Party Rights. No Stockholder may assign any of its rights or delegate any of its obligations under this Agreement without
the prior written consent of Buyer. This Agreement will apply to, be binding in all respects upon, and inure to the benefit of each of
the respective successors, personal or legal representatives, heirs, distributes, devisees, legatees, executors, administrators and permitted
assigns of any Stockholder and the successors and permitted assigns of Buyer. Nothing expressed or referred to in this Agreement will
be construed to give any Person, other than the parties to this Agreement, any legal or equitable right, remedy or claim under or with
respect to this Agreement or any provision of this Agreement except such rights as may inure to a successor or permitted assignee under
this Section 7.8.

 

7.9
Enforcement of Agreement. Each Stockholder acknowledges and agrees that Buyer could be damaged irreparably if any of the provisions
of this Agreement are not performed in accordance with their specific terms and that any breach of this Agreement by any Stockholder
could not be adequately compensated by monetary damages. Accordingly, each Stockholder agrees that, (a) it will waive, in any action
for specific performance, the defense of adequacy of a remedy at law, and (b) in addition to any other right or remedy to which Buyer
may be entitled, at law or in equity, Buyer will be entitled to enforce any provision of this Agreement by a decree of specific performance
and to temporary, preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of
this Agreement, without posting any bond or other undertaking.

 

7.10
Waiver. The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither any failure nor any
delay by a party in exercising any right, power or privilege under this Agreement, the Proxy or any of the documents referred to in this
Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power or privilege
will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege.
To the maximum extent permitted by applicable Law, (a) no claim or right arising out of this Agreement, the Proxy or any of the documents
referred to in this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the claim or right
unless in a written document signed by the other party, (b) no waiver that may be given by a party will be applicable except in the specific
instance for which it is given, and (c) no notice to or demand on one party will be deemed to be a waiver of any obligation of that party
or of the right of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement,
the Proxy or the documents referred to in this Agreement.

 

    	Exh. C-7

     

    

 

7.11
Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York, without
giving effect to that body of laws pertaining to conflict of laws which would result in the applicability of the law of any other state.

 

7.12
Choice of Forum. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated
hereby may be instituted in the federal courts of the United States or the courts of the State of New York in each case located in the
City of New York and County of New York, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such
suit, action or proceeding. Service of process, summons, notice or other document by mail to such party’s address set forth herein
shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or any proceeding in such courts and irrevocably waive
and agree not to plead or claim in any such court that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum.

 

7.13
Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed to be an original, but
all of which, taken together, will constitute one and the same instrument. An electronic copy of a party’s signature (including
signatures in Adobe PDF or similar format) shall be deemed an original signature for purposes hereof.

 

7.14
Expenses. Except as otherwise provided in this Agreement, all costs and expenses incurred in connection with this Agreement and
the transactions contemplated hereby will be paid by the party incurring such expenses.

 

7.15
Headings; Construction. The headings contained in this Agreement are for reference purposes only and will not affect in any way
the meaning or interpretation of this Agreement. In this Agreement (a) words denoting the singular include the plural and vice versa,
(b) “it” or “its” or words denoting any gender include all genders and (c) the word “including” means
“including without limitation,” whether or not expressed.

 

[Signature
page follows]

 

    	Exh. C-8

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Voting Agreement to be duly executed as of the day and year first above written.

 

	 	BUYER:
	 	 
	 	BRIGHT
    GREEN CORPORATION
	 	 
	 	By:	                 
	 	Name:	 
	 	Title: 	 
	 	 	 
	 	Address:
	 	 
	 	Email
    Address:

 

Signature Page to Voting Agreement

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Voting Agreement to be duly executed as of the day and year first above written.

 

STOCKHOLDERS:

 

	INDIVIDUAL: 	 	PARTNERSHIP, CORPORATION,
	 	 	LLC, TRUST OR OTHER ENTITY:
	 	 	 	                    
	 	 	PHYTO
	 	 	 	 
	 	 	By:	 
	(Print Name)	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 
	(Signature)	 	 	 
	 	 	Address:
	 	 	 	 
	 	 	Email Address:
	(Jurisdiction of Residence)	 	 	 
	 	 	EQUIPPED
	 	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 
	 	 	 	 
	 	 	Address:
	 	 	 	 
	 	 	Email Address:
	 	 	 	 
	 	 	TPR	 
	 	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 
	 	 	 	 
	 	 	Address:
	 	 	 	 
	 	 	Email Address

 

Signature
Page to Voting Agreement

 

    	 

     

    

 

SCHEDULE
A

 

	Name and Contact Information of Stockholder	 	Company Shares Beneficially Owned by such Stockholder	 
	Phytotherapeutix Holdings Ltd.

Address: Bretton House, Bell Meadow Business Park, Park Lane, Pulford, Chester, United Kingdom, CH4 9EP Attention: Mr. Colin Stott 

Email: cs@alterolabio.com
	 	 	112,746,006	 
	 	 	 	 	 
	Equipped4 Holdings Limited
  
 Address: Bretton House, Bell Meadow Business Park, Park Lane, Pulford, Chester, United Kingdom, CH4 9EP Attention: Mr. Dominic Schiller
  
 Email: ds@alterolabio.com
	 	 	112,746,006	 
	 	 	 	 	 
	TPR Global Limited
  
 Address: Bretton House, Bell Meadow Business Park, Park Lane, Pulford, Chester, United Kingdom, CH4 9EP Attention: Mr. Timothy Rogers
  
 Email: tr@alterolabio.com
	 	 	112,746,006	 

 

    	 

     

    

 

EXHIBIT
A

 

IRREVOCABLE PROXY

 

From
and after the date hereof and until the Termination Date (as defined below), on which date this irrevocable proxy (the “Proxy”)
will terminate and be of no further force or effect, the undersigned stockholder (“Stockholder”) of ALTEROLA
BIOSCIENCES, INC., a Nevada corporation (the “Company”), hereby irrevocably (to the fullest extent permitted
by Nevada law) grants to, and appoints, BRIGHT GREEN CORPORATION, a Delaware corporation (the “Buyer”), and
any designee of Buyer, and each of them individually, as the sole and exclusive attorney and proxy of the undersigned, with full power
of substitution and re-substitution, to vote the Subject Shares (as defined in the Voting Agreement) or to issue instructions to the
record holder to vote the Subject Shares, or grant a consent or approval in respect of the Subject Shares or issue instructions to the
record holder to grant a consent or approval in respect of the Subject Shares, in a manner consistent with Section 2.2 of the Voting
Agreement (as defined below). For the avoidance of doubt, this appointment of Proxy only applies to the matter of voting upon the aspects
regarding the “Merger” and “Merger Agreement” (as defined in the Voting Agreement). It does not apply to the
Stockholder’s voting on any other business matters pertaining to the Company. This Proxy and its continuance of grant is contingent
upon BRIGHT GREEN CORPORATION ensuring that the terms of the deal for the complete acquisition of Alterola Biotech Inc. are of no less
value than as specified in the BRIGHT GREEN CORPORATION Press Release dated August 30, 2022 and the terms of the signed Letter of Intent
(dated August 25, 2022) between the Company and the Buyer where the valuation of the Company was determined to be US$50 million. Subject
to confirmation of each Company shareholder qualifying as an “accredited investor”, it is anticipated that the balance of
the Enterprise value of the Company will be paid as 20% of each shareholding in cash and the remaining 80% in BRIGHT GREEN CORPORATION
stock, but the combination of stock and cash to be paid as consideration may be subject to change as required by law and following the
assessment and qualification of each shareholder. For the avoidance of doubt, the final division of payment may be altered in order to
comply with applicable law, including based on whether any Company shareholders are determined not to meet the requirements of being
an “accredited investor”, and the balance of the consideration will be determined following this assessment and included
in the definitive agreement prior to close of a Merger.

 

Upon
the undersigned’s execution of this Proxy, any and all prior proxies given by the undersigned with respect to any Subject Shares
relating to the voting rights expressly provided herein pertaining to the “Merger” and “Merger Agreement” are
hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect to the Subject Shares relating to such voting
rights pertaining to the “Merger” and “Merger Agreement” at any time prior to the Termination Date, on which
date this proxy will terminate and be of no further force or effect.

 

This
Proxy is irrevocable, is coupled with an interest and is granted pursuant to that certain Voting Agreement (as amended from time to time,
the “Voting Agreement”) of even date herewith, by and among Buyer and Stockholder, and is granted in consideration
of Buyer entering into the Merger Agreement (as defined in the Voting Agreement). As used herein, the term “Termination Date,”
and all capitalized terms used herein and not otherwise defined, will have the meanings set forth in the Voting Agreement. The Stockholder
agrees that this Proxy will be irrevocable until the Termination Date, on which date this proxy will terminate and be of no further force
or effect, and is coupled with an interest sufficient at law to support an irrevocable proxy and given to Buyer as an inducement to enter
into the Merger Agreement and, to the extent permitted under applicable law, will be valid and binding on any Person to whom Stockholder
may transfer any of his, her or its Subject Shares whether as permitted by or in breach of the Voting Agreement. The Stockholder
hereby ratifies and confirms all that such irrevocable proxy may lawfully do or cause to be done by virtue hereof.

 

    	 

     

    

 

The
attorneys and proxies named above, and each of them, are hereby authorized and empowered by the undersigned, at any time prior to
the Termination Date, on which date this Proxy will terminate and be of no further force or effect, to act as the
undersigned’s attorney and proxy to vote the Subject Shares, and to exercise all voting and other rights of the undersigned
with respect to the Subject Shares (including, without limitation, the power to execute and deliver written consents pursuant to
Nevada law), at every annual, special or adjourned meeting of the stockholders of the Company and in every written consent in lieu
of such meeting in a manner consistent with Section 2.2 of the Voting Agreement. Provided, however, that this Proxy will not limit
the right of any Stockholder to vote at any meeting or to act by written consent in a manner consistent with the Voting
Agreement.

 

This
Proxy will be binding upon the heirs, estate, executors, personal representatives, successors and assigns of Stockholder (including any
transferee of any of the Subject Shares), and all authority herein conferred or agreed to be conferred will survive the death or incapacity
of the Stockholder.

 

If
any provision of this Proxy or any part of any such provision is held under any circumstances to be invalid or unenforceable in any jurisdiction,
then (a) such provision or part thereof will, with respect to such circumstances and in such jurisdiction, be deemed amended to conform
to applicable laws so as to be valid and enforceable to the fullest possible extent, (b) the invalidity or unenforceability of such provision
or part thereof under such circumstances and in such jurisdiction will not affect the validity or enforceability of such provision or
part thereof under any other circumstances or in any other jurisdiction, and (c) the invalidity or unenforceability of such provision
or part thereof will not affect the validity or enforceability of the remainder of such provision or the validity or enforceability of
any other provision of this Proxy. Each provision of this Proxy is separable from every other provision of this Proxy, and each part
of each provision of this Proxy is separable from every other part of such provision.

 

With
respect to any Subject Shares that are Beneficially Owned (as defined in the Voting Agreement) by the Stockholder but are not held of
record by the Stockholder, the Stockholder shall take all action necessary to cause the record holder of such Subject Shares to grant
the irrevocable proxy and take all other actions provided for in this proxy with respect to such Subject Shares.

 

(Signature
page follows)

 

    	2

    	 

    

 

Dated:
October 03, 2022

 

	INDIVIDUAL: 	 	PARTNERSHIP, CORPORATION,
	 	 	LLC, TRUST OR OTHER ENTITY:
	 	 	 	                    
	 	 	PHYTO
	 	 	 	 
	 	 	By:	 
	(Print Name)	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 
	(Signature)	 	 	 
	 	 	Address:
	 	 	 	 
	 	 	Email Address:
	(Jurisdiction of Residence)	 	 	 
	 	 	EQUIPPED
	 	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 
	 	 	 	 
	 	 	Address:
	 	 	 	 
	 	 	Email Address:
	 	 	 	 
	 	 	TPR	 
	 	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 
	 	 	 	 
	 	 	Address:

 

Signature
Page to Irrevocable ProxyExhibit 10.1

 

SEPARATION, CONSULTING AND RELEASE AGREEMENT

 

This Separation, Consulting
and Release Agreement (this “Agreement”), delivered October 4, 2022, confirms the following understandings
and agreements between PharmaCyte Biotech, Inc. (“Company”) and Kenneth L. Waggoner (“you”
or “your”).

 

In consideration of the promises
set forth herein, you and the Company agree as follows:

 

1.             
Opportunity for Review; Acceptance.

 

(a)           
You have until 5:00 P.M. Pacific Standard Time on October 25, 2022 (“Review Period”), to review
and consider this Agreement. To accept this Agreement, and the terms and conditions contained herein, prior to the expiration of the Review
Period, you must execute and date this Agreement where indicated below and return the executed copy of this Agreement to Joshua Silverman
(“Company Representative”), by email (jsilverman@parkfieldfund.com). You acknowledge that, to the extent there
are changes made to the terms of this Agreement, whether they are material or immaterial, the Review Period is not recommenced.

 

(b)          
Notwithstanding anything contained herein to the contrary, this Agreement will not become effective or enforceable for a period
of seven (7) calendar days following the date of your execution of this Agreement (“Revocation Period”), during
which time you may revoke your acceptance of this Agreement by notifying the Company Representative, in writing, as specified above. To
be effective, such revocation must be received by the Company Representative no later than 5:00 P.M. Pacific Standard Time on the seventh
(7th) calendar day following your execution of this Agreement. Provided that this Agreement is executed during the Review Period,
and you do not revoke it during the Revocation Period, the eighth (8th) day following the date on which this Agreement is executed
and delivered to the Company shall be its effective date (“Effective Date”). In the event that you fail to execute
and deliver this Agreement prior to the expiration of the Review Period, this Agreement will be null and void and of no effect, and neither
the Company nor any other member of the Company Group (as defined below) will have any obligations hereunder. In the event that you revoke
this Agreement during the Revocation Period, this Agreement will be null and void and of no effect, and the Company will have no obligations
hereunder.

 

2.             
Employment Status; Accrued Benefits; and Separation Benefits.

 

(a)          
Employment Status. You acknowledge and agree that your employment with the Company and its direct and indirect subsidiaries
and affiliates (collectively, with the Company, “Company Group”), will terminate effective as of the close of
business on October 6, 2022 as a result of your voluntary resignation (“Separation Date”), and after the
Separation Date, you will not represent yourself as being an employee, officer, director, agent, or representative of the Company or any
other member of the Company Group. You hereby confirm your resignations from all offices, directorships, trusteeships, committee memberships
and fiduciary and other capacities held with, or on behalf of, the Company Group effective as of the Separation Date, including as a member
of the Board of Directors of the Company (“Board”), and your execution of this Agreement will be deemed the
grant by you to the officers of the Company of a limited power of attorney to sign in your name and on your behalf any such documentation
as may be required to be executed solely for the limited purposes of effectuating such resignations. You agree that within five (5) business
days following the Separation Date, you will update your accounts or profiles on any social media platform (including, but not limited
to, Facebook, Twitter or LinkedIn) to reflect that you are no longer actively employed by or affiliated with the Company.

 

 

 

    	 	1	 

     

    

 

(b)          
Accrued Benefits. The Separation Date shall be the termination date of your employment for purposes of participation in
and coverage under all employee benefit plans and programs or arrangements sponsored by or through the Company and any other member of
the Company Group. You will be paid for (i) all of your earned but unpaid salary through the Separation Date on or prior to the Company’s
next regularly scheduled payroll date on or following the Separation Date, or earlier to the extent otherwise required by applicable law,
(ii) any reasonable business expenses incurred by you prior to the Separation Date and properly submitted in accordance with the
Company’s policies and procedures as of the Separation Date and which are set forth on Exhibit A. In addition, you will
be entitled to continued medical and health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”)
at your sole expense, and additional information concerning such benefits will be provided to you under separate cover following the Separation
Date.

 

(c)           
Separation Benefits. In consideration of your release and waiver of claims set forth in paragraph 3 and subject to
your execution and delivery of this Agreement, and non-revocation thereof, and continued compliance with this Agreement, you will receive
a lump sum payment equal to $216,667 within five (5) business days following the Effective Date (the “Consideration”).

 

(d)          
Full Discharge. You acknowledge and agree that the payment(s) and other benefits provided pursuant to this paragraph ‎2
are in full satisfaction and discharge of any and all liabilities and obligations of the Company or any other member of the Company Group
to you, monetarily or with respect to employee benefits or otherwise, including but not limited to any and all obligations (i) arising
under that certain Amended and Restated Executive Compensation Agreement, by and between you and the Company, dated May 8, 2022 (“Employment
Agreement”), (ii) arising under any other alleged written or oral employment agreement, policy, plan or procedure of
the Company or any other member of the Company Group, (iii) arising under any alleged understanding or arrangement between you and
the Company or any other member of the Company Group (other than claims for accrued and vested benefits under an employee benefit, insurance,
or pension plan of the Company or any other member of the Company Group (excluding any severance or similar plan or policy), subject to
the terms and conditions of such plan(s)), and (iv) in respect of any unvested equity awards and any commitment or promise by the
Company or the Board to grant you an equity award of the Company, whether vested or unvested as of the date hereof, or to recommend to
the stockholders of the Company approval to grant you an equity award of the Company, including without limitation the option to purchase
529,000 shares of common stock of the Company and 150,800 restricted stock units approved by the Board on April 14, 2022 (collectively,
the “2022 Grant”). Notwithstanding the foregoing, nothing in this Agreement shall be construed to forfeit,
or restrict the option to purchase 15,000 shares of common stock of the Company and 23,000 restricted stock units previously granted to
you. You further acknowledge and agree that as of the Separation Date, you do not have any accrued but unused paid time off.

 

(e)           
Taxes. The Consideration is subject to withholding for all applicable taxes, including but not limited to income, employment,
and social insurance taxes, as shall be required by law.

 

3.             
Release and Waiver of Claims.

 

(a)           
As used in this Agreement, the term “claims” will include all claims, covenants, warranties, promises, undertakings,
actions, suits, causes of action, obligations, debts, accounts, attorneys’ fees, judgments, losses and liabilities, of whatsoever
kind or nature, in law, equity or otherwise.

 

 

 

    	 	2	 

     

    

 

(b)           
For and in consideration of the Consideration described in paragraph ‎2 above, and other good and valuable
consideration, you, for and on behalf of yourself and your heirs, administrators, spouses, executors and assigns, as of the date hereof,
do fully and forever release, remise and discharge each member of the Company Group and their successors and assigns, together with their
respective current and former officers, directors, partners, members, stockholders (including any management company of a stockholder),
employees and agents (collectively, and with the Company, the “Company Parties”) from any and all claims
whatsoever up to the date hereof which you had, may have had, or now have against the Company Parties, whether known or unknown, for or
by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to your employment or the termination
of your employment with the Company or any member of the Company Group, or your role as a stockholder of the Company, officer, or former
member of the Board (including without limitation any claims to advancement or indemnification), whether for tort, breach of express or
implied employment contract, breach of fiduciary duty, intentional infliction of emotional distress, retaliation, wrongful termination,
unjust dismissal, defamation, libel or slander, or under any federal, state or local law dealing with discrimination based on age, race,
sex, national origin, handicap, religion, disability or sexual orientation, in each case, whether brought in your individual capacity
or derivatively on behalf of the Company or another person. This release of claims includes, but is not limited to, all claims arising
under the Age Discrimination in Employment Act (the “ADEA”), Title VII of the Civil Rights Act of 1964,
the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the Equal Pay Act, the Worker Adjustment
and Retraining Notification Act, the Employee Retirement Income Security Act (excluding claims for accrued, vested benefits under an employee
pension benefit plan of the Company Parties), and any Federal, state or foreign securities laws, each as may be amended from time to time,
and all other federal, state and local laws, the common law and any other purported restriction on an employer’s right to terminate
the employment of employees. You intend the release contained herein to be a general release of any and all claims to the fullest extent
permissible by law and for the provisions regarding the release of claims against the Company Parties to be construed as broadly as possible,
and hereby incorporate in this release similar federal, state or other laws, all of which you also hereby expressly waive.

 

(c)           
You understand and agree that claims or facts in addition to or different from those which are now known or believed by you to
exist may hereafter be discovered, but it is your intention to fully and forever release, remise and discharge all claims which you had,
may have had, or now have against the Company Parties, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent
or noncontingent, without regard to the subsequent discovery or existence of such additional or different facts. Without limiting the
foregoing, by signing this Agreement, you expressly waive and release any provision of law that purports to limit the scope of a general
release, including any and all rights and benefits under Section 1542 of the Civil Code of the State of California (or any analogous
law of any other state, to the extent applicable), which provides as follows:

 

“A GENERAL RELEASE DOES NOT EXTEND TO
CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE,
AND THAT IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

 

(d)           
You acknowledge and agree that as of the date you execute this Agreement, you have no knowledge of any facts or circumstances that
give rise or could give rise to any claims under any of the laws listed in the preceding paragraphs.

 

(e)           
Notwithstanding any provision of this Agreement to the contrary, by executing this Agreement, you are not releasing any claims
relating to: (i) your rights with respect to payment of amounts under this Agreement; (ii) your right to accrued, vested benefits
due to terminated employees under any employee benefit plan of the Company or any other member of the Company Group in which you participated
(excluding any severance or similar plan or policy), in accordance with the terms thereof (including your right to elect COBRA continuation
coverage); (iii) any claims that cannot be waived by law or that arise after the date on which you execute this Agreement; (iv) any
rights or claims under the ADEA that may arise after the date that you execute this Agreement; or (v) your right to directors and officers
liability insurance, as provided by, and in accordance with the terms of, applicable law and the Company’s governing documents.
For the avoidance of doubt, you acknowledge and agree that the release contained in this Agreement includes all claims relating to or
arising from the 2022 Grant.

 

 

 

    	 	3	 

     

    

 

(f)            
You acknowledge and agree that, by virtue of the foregoing, you have waived any relief available to you (including without limitation,
monetary damages, equitable relief and reinstatement) under any of the claims and/or causes of action waived in this paragraph ‎3.
Therefore you agree that you will not accept any award or settlement from any source or proceeding (including but not limited to any proceeding
brought by any other person or by any government agency) with respect to any claim or right waived in this Agreement.

 

(g)           
You acknowledge and agree that as of the date of this Agreement, you have reported all accidents, injuries or illnesses relating
to or arising from your employment with the Company or the Company Group and that you have not suffered any on-the-job injury or illness
for which you have not yet filed a claim.

 

4.             
Knowing and Voluntary Waiver. You expressly acknowledge and agree that you:

 

(a)           
are able to read the language, and understand the meaning and effect, of this Agreement;

 

(b)           
have no physical or mental impairment of any kind that has interfered with your ability to read and understand the meaning of this
Agreement or its terms, and that you are not acting under the influence of any medication, drug or chemical of any type in entering into
this Agreement;

 

(c)            are
specifically agreeing to the terms of the release contained in this Agreement because the Company has agreed to provide you the Consideration,
which the Company has agreed to provide because of your agreement to accept it in full settlement of all possible claims you might have
or ever had against the Company Parties, and because of your execution of this Agreement;

 

(d)           
acknowledge that but for your execution of this Agreement, you would not be entitled to the Consideration;

 

(e)           
had or could have the entire Review Period in which to review and consider this Agreement, and that if you execute this Agreement
prior to the expiration of the Review Period, you have voluntarily and knowingly waived the remainder of the Review Period;

 

(f)            
understand that, by entering into this Agreement, you do not waive rights or claims under the ADEA that may arise after the date
you execute this Agreement;

 

(g)           
have not relied upon any representation or statement not set forth in this Agreement made by the Company Group or any of its representatives;

 

(h)           
were advised to consult with your attorney regarding the terms and effect of this Agreement; and

 

(i)            
have signed this Agreement knowingly and voluntarily.

 

5.             
No Suit. You represent and warrant that you have not previously filed, and to the maximum extent permitted by law agree
that you will not file or encourage or assist anyone else in filing, a complaint, charge or lawsuit against any of the Company Parties.
If, notwithstanding this representation and warranty, you have filed or file such a complaint, charge or lawsuit, you agree that you shall
cause such complaint, charge or lawsuit to be dismissed with prejudice and shall pay any and all costs required in obtaining dismissal
of such complaint, charge or lawsuit, including without limitation the attorneys’ fees of any of the Company Parties against whom
you have filed such a complaint, charge, or lawsuit. This paragraph 5 shall not apply, however, to any non-waivable right to file
a charge with the U.S. Equal Employment Opportunity Commission (the “EEOC”) or similar state agency; provided,
however, that if the EEOC or similar state agency pursues any claims relating to your employment with the Company or any member
of the Company Group, you agree that you shall not be entitled to recover any monetary damages or any other remedies or benefits as a
result and that this Agreement and the Consideration will control as the exclusive remedy and full settlement of all such claims by you,
to the maximum extent permitted by law.

 

 

 

    	 	4	 

     

    

 

6.             
Post-Termination Consulting Services.

 

(a)           
Consulting Period. You agree that during the twelve (12) month period immediately following the Separation Date (“Consulting
Period”), you will serve as an independent contractor of the Company and will facilitate the orderly transfer of work to
other employees of the Company, including to a new Chief Executive Officer of the Company. In furtherance of the foregoing, during the
Consulting Period, you specifically agree to cooperate with members of the Board, management, external counsel to the Company, your direct
reports and other employees of the Company Group, transfer account information, provide information, answer questions, assist the Company
in the negotiation of invoices, and provide guidance as reasonably requested by such aforementioned persons relating to any matter on
which you will have worked prior to the Separation Date or of which you have knowledge (“Consulting Services”).
You agree to perform the Consulting Services as and when reasonably requested by the Company from time to time from your home office,
and will not be required to travel on behalf of the Company to perform the Consulting Services. You agree to perform the Consulting Services
in good faith, and during the Consulting Period, you agree to abide by the Company’s policies as may be in place from time to time.
You may not assign your rights or delegate your obligations under this paragraph 6 either in whole or in part without the prior written
consent of the Company.

 

(b)           
Consulting Fee; Expenses. In consideration for your provision of the Consulting Services in accordance with the terms of
this Agreement, you will be entitled to receive $433,333, payable in twelve (12) installments at the end of each month of the Consulting
Period in arrears (“Consulting Fee”).

 

(c)           
Termination. The obligations under this paragraph 6 will automatically expire on the last day of the Consulting Period
without further obligation by either party under this paragraph 6. Notwithstanding the foregoing, the Company may terminate the Consulting
Period upon your material breach of any provision of this Agreement or the Restrictive Covenants (as defined below); provided,
that prior to such termination, you will be provided notice from the Company setting forth in reasonable detail the basis on which the
Company is terminating the Consulting Period and, if the condition is curable, you will then have fifteen (15) business days from receipt
of such notice during which you may remedy the condition. If full cure is made by you within such fifteen (15) business day cure period,
as determined by the Board, your engagement will be deemed to have continued under and subject to the provisions of this paragraph 6
for the remainder of the Consulting Period.

 

(d)          
Taxes; Independent Contractor Status. During the Consulting Period, you shall be an independent contractor and not an employee
of the Company, and shall have no right or authority to make or undertake any promise, warranty, or representation or to execute any contract
or otherwise assume any obligation or responsibility, in the name of the Company or any member of the Company Group. As an independent
contractor providing the Consulting Services, you will be solely responsible for remitting to the applicable taxing authorities all applicable
taxes payable in respect of amounts payable to you under paragraph 6(b) above, and the Company will not withhold for taxes from any
such amounts. In addition, you understand and agree that you are not eligible by virtue of your engagement as a consultant hereunder to
participate in any of the employee benefit plans and programs or arrangements of the Company Group, including, without limitation, any
bonus, stock option, pension, profit sharing, medical, dental, disability or life insurance or similar benefits provided to employees
of the Company Group (which participation shall have terminated as of the Separation Date), or in any vacation or illness payments, except
as set forth in the Consideration in Section 2(c) and the option to purchase 15,000 shares of common stock of the Company and 23,000 restricted
stock units previously granted to you. In the event that this consulting arrangement is reclassified as employment by any governmental
agency or court, you further agree that you will not seek to participate in or benefit from any of the employee benefit plans or programs
of the Company Group as a result of such reclassification. You agree that, during and after the Consulting Period, you will indemnify,
defend and hold the Company harmless from all taxes, interest, penalties, damages, liabilities, losses and expenses, including reasonable
legal fees and expenses of attorneys and other professionals, arising from your failure or alleged failure to make the required reports
and payments for applicable taxes. In addition, during and after the Consulting Period, you will indemnify, defend and hold the Company
harmless with respect to any amounts that you may be required to pay to any taxing authority as required withholding or the employer portion
of any employment taxes due as a result of any claim by such taxing authority that you were an employee of the Company, including, without
limitation, any interest or penalties imposed as a result of such claim.

 

 

 

    	 	5	 

     

    

 

7.             
No Re-Employment. You hereby agree to waive any and all claims to re-employment with the Company or any other member of
the Company Group. You affirmatively agree not to seek further employment with the Company or any other member of the Company Group. You
acknowledge that if you re-apply for or seek employment with the Company or any other member of the Company Group, the Company’s
or any other member of the Company Group’s refusal to hire you based on this provision will provide a complete defense to any claims
arising from your attempt to apply for employment.

 

8.            
Company Release. For and in consideration of your release of claims against the Company Parties as set forth in paragraph ‎‎3
above, the Restrictive Covenants and other good and valuable consideration, the Company, for and on behalf of the Company Group, as of
the date hereof, does fully and forever release, remise and discharge you and your heirs, administrators and assigns from any and all
claims whatsoever up to the date hereof which it had, may have had, or now has against you, whether known or unknown, for or by reason
of any matter, cause or thing whatsoever, including any claim arising out of or attributable to your employment or the termination of
your employment with the Company or any member of the Company Group, but excluding (i) claims with respect to any obligation under
this Agreement, the Restrictive Covenants or the governing documents of the Company Group; (ii) any claims that cannot be waived
by law; (iii) claims that are based upon any of your acts that involve fraud, misappropriation, embezzlement, or theft, in each case,
of which the Board does not have knowledge of as of the date hereof; and (iv) cross-claims in any stockholder derivative lawsuit.
The Company intends the release contained herein to be a general release of any and all claims to the fullest extent permissible by law
and for the provisions regarding the release of claims to be construed as broadly as possible, and hereby incorporates in this release
similar federal, state or other laws, all of which the Company also hereby expressly waives. The Company understands and agrees that claims
or facts in addition to or different from those which are now known or believed by the Company to exist may hereafter be discovered, but
it is the Company’s intention to fully and forever release, remise and discharge all claims which it had, may have had, or now has
against you, whether known or unknown, suspected or unsuspected, asserted or unasserted, contingent or noncontingent, without regard to
the subsequent discovery or existence of such additional or different facts. Without limiting the foregoing, by signing this Agreement,
the Company expressly waives and releases any provision of law that purports to limit the scope of a general release.

 

9.             
Successors and Assigns. The provisions hereof shall inure to the benefit of your heirs, executors, administrators, legal
personal representatives and assigns and shall be binding upon your heirs, executors, administrators, legal personal representatives and
assigns.

 

10.          
Severability; Third-Party Beneficiaries. If any provision of this Agreement shall be held by any court of competent jurisdiction
to be illegal, void or unenforceable, such provision shall be of no force and effect. The illegality or unenforceability of such provision,
however, shall have no effect upon and shall not impair the enforceability of any other provision of this Agreement. You acknowledge and
agree that each of the Company Parties shall be a third-party beneficiary to the releases set forth in paragraph ‎3 above,
with full rights to enforce this Agreement and the matters documented herein.

 

11.           
Non-Disparagement. You agree that you will make no disparaging or defamatory comments regarding any member of the Company
Group or their respective current or former directors, officers, employees, members, stockholders (including any management company of
a stockholder), or affiliates in any respect or make any comments concerning any aspect of your relationship with any member of the Company
Group or the conduct or events which precipitated your termination of employment from any member of the Company Group. The Company agrees
to direct the Company’s current directors and executive officers not to make any disparaging or defamatory comments regarding you
in any respect or make any comments concerning any aspect of your relationship with any member of the Company Group. Your obligations
under this paragraph ‎11 extend to, but are not limited to, text messages, e-mail communications, and comments or postings
on blogs, comment boards or social media websites including, but not limited to, Facebook, Twitter or LinkedIn. Further, nothing in this
Agreement prohibits you from speaking with law enforcement, the EEOC, any state or local division of human rights or fair employment agency,
or your attorney. This paragraph ‎11 shall not prevent the truthful testimony by
any individual or entity in a legal proceeding or pursuant to a governmental, administrative or regulatory investigation.

 

 

 

    	 	6	 

     

    

 

12.           
Cooperation.

 

(a)           
You agree that you will provide reasonable cooperation to the Company and/or any other member of the Company Group and its or their
respective counsel in connection with any investigation, administrative proceeding or litigation relating to any matter that occurred
during your employment in which you were involved or of which you have knowledge. The Company agrees to reimburse you for reasonable out-of-pocket
expenses incurred at the request of the Company with respect to your compliance with this paragraph ‎12(a).

 

(b)           
You agree that, in the event you are subpoenaed by any person or entity (including, but not limited to, any government agency)
to give testimony or provide documents (in a deposition, court proceeding or otherwise) which in any way relates to your employment by
the Company and/or any other member of the Company Group, you will give prompt written notice of such request to the Company Representative,
in writing, as specified above (or the Company Representative’s successor or designee), unless otherwise permitted by law, and will
make no disclosure until the Company and/or the other member of the Company Group has had a reasonable opportunity to contest the right
of the requesting person or entity to such disclosure. The Company agrees to reimburse you for reasonable out-of-pocket expenses incurred
at the request of the Company with respect to your compliance with this paragraph 12(b).

 

13.          
Affirmation of Continuing Obligations. You hereby acknowledge and agree that the execution of this Agreement does not alter
your obligations to any member of the Company Group under any confidentiality, non-compete, non-solicit, invention assignment, or similar
agreement or arrangement to which you are a party with any member of the Company Group (including, without limitation, the obligations
set forth in Sections 5-7 of your Employment Agreement (collectively, “Restrictive Covenants”)), which obligations
are hereby incorporated into this Agreement and shall survive the termination of your employment with the Company, and you hereby acknowledge,
reaffirm and ratify your continuing obligations to the Company Group pursuant to such agreements or arrangements. You further hereby acknowledge
that your continued compliance with these obligations is a condition of the Company’s agreement to engage you as a consultant during
the Consulting Period, and upon any breach of the Restrictive Covenants, the Company shall have grounds to terminate the Consulting Period,
subject to the cure right contained in paragraph 6.

 

14.           
Return of Property. You agree that you will promptly return to the Company, and you will retain no copies of, all property
belonging to the Company and/or any other member of the Company Group, including but not limited to all proprietary and/or confidential
information and documents (including any copies thereof) in any form belonging to the Company, keys, credit card, identification card
or badge, access card, employee handbook, disks, data files, thumb drives, and/or voicemail code and other office equipment, it being
understood that you may retain your Company-provided iPhone and laptop in order to perform the Consulting Services, and following the
end of the Consulting Period, you will promptly return such property to the Company. Except as may be necessary to provide the Consulting
Services, if you discover after the Separation Date that you have retained any proprietary and/or confidential information (including,
without limitation, proprietary and/or confidential information contained in any electronic documents or email systems in your possession
or control), you agree immediately upon discovery to send an email to the Company Representative to inform the Company of the nature and
location of the proprietary and/or confidential information that you have retained so that the Company may arrange to remove, recover,
and/or collect such information. You further acknowledge and agree that the Company shall have no obligation to provide the Consideration
described in paragraph ‎2 above, or engage you as a consultant during the Consulting Period described in paragraph 6
above, unless and until you have satisfied all your obligations pursuant to this paragraph ‎14.

 

15.          
Non-Admission. Nothing contained in this Agreement will be deemed or construed as an admission of wrongdoing or liability
on the part of you or any member of the Company Group. Accordingly, this Agreement may not be admissible in any forum as an admission,
but only in an action to enforce it.

 

 

 

    	 	7	 

     

    

 

16.          
Entire Agreement. This Agreement and the Restrictive Covenants constitute the entire understanding and agreement of the
parties hereto regarding the termination of your employment. This Agreement and the Restrictive Covenants supersede all prior negotiations,
discussions, correspondence, communications, understandings and agreements between the parties relating to the subject matter of this
Agreement and the Restrictive Covenants.

 

17.         
Governing Law; Jurisdiction; Arbitration. YOU HEREBY ACKNOWLEDGE AND AGREE THAT YOU WERE ASSISTED BY COUNSEL IN THE
NEGOTIATION OF THE TERMS OF THIS AGREEMENT, including designating the venue, forum, and the choice
of law to be applied. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF NEVADA, APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE, WITHOUT REGARD TO CONFLICT OF LAWS RULES.
BY EXECUTION OF THIS AGREEMENT, EACH PARTY TO THIS AGREEMENT HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF THE STATE OF NEVADA AND
FEDERAL COURTS LOCATED IN THE STATE OF NEVADA AND HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY IN CONNECTION WITH ANY DISPUTE ARISING UNDER
OR CONCERNING THIS AGREEMENT. ALL DISPUTES ARISING UNDER OR CONCERNING THIS AGREEMENT, AS WELL AS ALL CLAIMS ARISING OUT OF YOUR EMPLOYMENT
OR TERMINATION THEREOF, INCLUDING WITHOUT LIMITATION ALL CLAIMS FOR PAYMENT OF WAGES, DISCRIMINATION, RETALIATION, AND ALL OTHER CLAIMS
BASED ON ANY STATE, FEDERAL OR COMMON LAW WILL BE RESOLVED THROUGH BINDING ARBITRATION BEFORE A SINGLE ARBITRATOR. THE ARBITRATION SHALL
BE ADMINISTERED BY JAMS, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. IF JAMS CANNOT SERVE AS THE ARBITRATION ADMINISTRATOR,
THEN THE ARBITRATION WILL BE THROUGH THE AMERICAN ARBITRATION ASSOCIATION, UNDER ITS THEN APPLICABLE RULES FOR EMPLOYMENT DISPUTES. THE
EXCLUSIVE VENUE OF ANY SUCH ARBITRATION WILL BE LAS VEGAS, NEVADA. THE NON-PREVAILING PARTY
WILL PAY THE REASONABLE ATTORNEYS’ FEES AND COSTS OF THE PREVAILING PARTY. THE ARBITRATOR SHALL HAVE AUTHORITY TO ISSUE EQUITABLE
AND LEGAL RELIEF, INCLUDING WITHOUT LIMITATION INJUNCTIVE RELIEF AND MONETARY DAMAGES. ALL ARBITRATION PROCEEDINGS SHALL BE CONFIDENTIAL.

 

18.           
Remedies for Breach. You acknowledge that the provisions of this Agreement are reasonable and necessary for the protection
of the Company and that the Company may be irreparably damaged if these provisions are not specifically enforced. Accordingly, you agree
that, in addition to any other relief or remedies available to the Company, the Company shall be entitled to obtain appropriate temporary,
preliminary and permanent injunctive or other equitable relief for the purposes of restraining you from any actual or threatened breach
of or otherwise enforcing these provisions and no bond or security will be required in connection therewith.

 

19.           
Construction. The section or paragraph headings or titles herein are for convenience of reference only and shall not be
deemed a part of this Agreement. The parties hereto acknowledge and agree that each party has reviewed and negotiated the terms and provisions
of this Agreement and has had the opportunity to contribute to its revision. Accordingly, the rule of construction to the effect that
ambiguities are resolved against the drafting party, including, but not limited to Section 1654 of the California Civil Code, shall
not be employed in the interpretation of this Agreement. Rather, the terms of this Agreement shall be construed in a reasonable manner
to effect the intentions of both parties hereto and not in favor or against either party.

 

20.           
Section 409A. Payments and/or benefits under this Agreement are intended to be exempt from, or comply with, Section 409A
of the Internal Revenue Code of 1986, as amended (“Section 409A”), and this Agreement will be interpreted
to achieve this result. For purposes of this Agreement, each payment in a series of payments hereunder shall be deemed to be a separate
payment for purposes of Section 409A. In no event is the Company responsible for any tax or penalty owed by you (other than for withholding
obligations or other obligations applicable to employers, if any, under Section 409A) with respect to payments under this Agreement.

 

21.           
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
shall constitute one and the same instrument, and electronically delivered copies of executed counterparts shall be deemed to be originals
for all purposes.

 

***

 

 

 

    	 	8	 

     

    

 

IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date set forth below.

 

 

	 	PharmaCyte Biotech, Inc.
	 	 
	 	 
	 	By:	/s/ Joshua Silverman                                               
	 	 	Joshua Silverman
	 	 	Interim Chief Executive Officer
	 	 	Dated: 10/6/2022
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	/s/ Kenneth L. Waggoner                                           
	 	 	Kenneth L. Waggoner
	 	 	Dated: 10/5/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	9	 

     

    

 

Exhibit A

 

Business Expenses

 

1.     
None

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]